|
**Overview**: Ovarian Reserve Panel**Introduction**: The Ovarian Reserve Panel is a diagnostic tool designed to assess ovarian reserve using serum samples. In India, diminished ovarian reserve contributes to ~30-40 percent of infertility cases, with early menopause (~46-47 years average) more common in rural/low-SES women due to malnutrition, smoking, or multiparity. High morbidity from under-testing leading to delayed fertility counseling or ART, causing prolonged childlessness or psychological distress. Per reproductive medicine practices aligned with ICMR, FOGSI, and Indian Society for Assisted Reproduction guidelines, the test employs immunoassay for AMH, FSH, and estradiol over 1-2 days with high accuracy, valuable for predicting ovarian response in IVF or natural conception (AMH best marker). This diagnostic falls under reproductive screening and targets women with infertility, irregular cycles, or advanced maternal age, addressing accurate detection to guide ART timing or oocyte cryopreservation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise fertility assessment and reducing infertility burden. Its serum-based approach ensures reliable hormonal profiling.**Other Names**: Ovarian Res Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: AMH/FSH panel standard; in India, routine in IVF clinics.**Purpose**: The test assesses 3 parameters including AMH to guide ovarian reserve assessment, predict fertility potential, inform ART.**Test Parameters**: 1. AMH, 2. FSH, 3. Estradiol.**Pretest Condition**: Fasting 10-12 hours recommended; day 2-3 of cycle preferred.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cycle regularity, infertility duration.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of low reserve including infertility, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or oral contraceptives can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low AMH/high FSH indicates diminished reserve, necessitating specialist input.**Specialist Consultation**: Reproductive endocrinologists should be consulted for management.**Additional Supporting Tests**: Antral follicle count, AFC ultrasound for confirmation.**Test Limitations**: Day-specific; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Infertility Studies India 2023. |
